AMI Asset Management Corp Has $50.88 Million Stock Position in Insulet Corporation $PODD

AMI Asset Management Corp decreased its stake in shares of Insulet Corporation (NASDAQ:PODD - Free Report) by 5.4% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 161,953 shares of the medical instruments supplier's stock after selling 9,166 shares during the quarter. Insulet makes up 2.9% of AMI Asset Management Corp's portfolio, making the stock its 10th largest position. AMI Asset Management Corp owned 0.23% of Insulet worth $50,883,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Nissay Asset Management Corp Japan ADV raised its stake in shares of Insulet by 0.6% during the 1st quarter. Nissay Asset Management Corp Japan ADV now owns 8,462 shares of the medical instruments supplier's stock worth $2,222,000 after acquiring an additional 48 shares in the last quarter. Mather Group LLC. grew its position in Insulet by 4.4% during the 2nd quarter. Mather Group LLC. now owns 1,147 shares of the medical instruments supplier's stock worth $360,000 after purchasing an additional 48 shares during the last quarter. Brooklyn Investment Group grew its position in Insulet by 7.0% during the 1st quarter. Brooklyn Investment Group now owns 795 shares of the medical instruments supplier's stock worth $209,000 after purchasing an additional 52 shares during the last quarter. OLD National Bancorp IN grew its position in Insulet by 6.7% during the 1st quarter. OLD National Bancorp IN now owns 880 shares of the medical instruments supplier's stock worth $231,000 after purchasing an additional 55 shares during the last quarter. Finally, Cooper Financial Group grew its position in Insulet by 5.7% during the 1st quarter. Cooper Financial Group now owns 1,079 shares of the medical instruments supplier's stock worth $283,000 after purchasing an additional 58 shares during the last quarter.

Insulet Stock Performance

PODD opened at $305.98 on Thursday. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.26 and a quick ratio of 1.81. The firm has a fifty day moving average price of $320.45 and a 200 day moving average price of $297.85. Insulet Corporation has a 1 year low of $225.37 and a 1 year high of $353.50. The stock has a market cap of $21.54 billion, a P/E ratio of 93.00, a P/E/G ratio of 2.56 and a beta of 1.40.

Insulet (NASDAQ:PODD - Get Free Report) last posted its earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.92 by $0.25. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The firm had revenue of $649.10 million during the quarter, compared to analysts' expectations of $612.31 million. During the same period in the previous year, the business posted $0.55 EPS. The business's revenue was up 32.9% compared to the same quarter last year. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Equities research analysts anticipate that Insulet Corporation will post 3.92 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts have weighed in on PODD shares. JPMorgan Chase & Co. boosted their target price on shares of Insulet from $340.00 to $415.00 and gave the stock an "overweight" rating in a research report on Friday, September 12th. Wall Street Zen raised shares of Insulet from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. Wells Fargo & Company boosted their target price on shares of Insulet from $330.00 to $350.00 and gave the stock an "overweight" rating in a research report on Friday, August 8th. Barclays boosted their target price on shares of Insulet from $266.00 to $300.00 and gave the stock an "equal weight" rating in a research report on Thursday, August 21st. Finally, Truist Financial initiated coverage on shares of Insulet in a report on Monday, June 16th. They issued a "buy" rating and a $365.00 price objective on the stock. Sixteen analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $345.47.

Insider Buying and Selling at Insulet

In related news, SVP Prem Singh sold 687 shares of the business's stock in a transaction on Monday, September 8th. The shares were sold at an average price of $347.49, for a total value of $238,725.63. Following the completion of the transaction, the senior vice president directly owned 3,456 shares in the company, valued at $1,200,925.44. The trade was a 16.58% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Laetitia Cousin sold 797 shares of the business's stock in a transaction on Monday, September 8th. The shares were sold at an average price of $348.81, for a total transaction of $278,001.57. Following the completion of the transaction, the senior vice president owned 3,890 shares of the company's stock, valued at approximately $1,356,870.90. This represents a 17.00% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.39% of the company's stock.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.

Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Corporation (NASDAQ:PODD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.